Document is current
Any future updates will be listed below
-
Authors
,
Gu, Wei
Yildirimman, Reha
Van der Stuyft, Emmanuel
Verbeeck, Denny
Herzinger, Sascha
Satagopam, Venkata
Barbosa-Silva, Adriano
Schneider, Reinhard
Lange, Bodo
Lehrach, Hans
Guo, Yike
Henderson, David https://orcid.org/0000-0002-6433-200X
Rowe, Anthony
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (115234 OncoTrack, 115446 eTRIKS)
- License Information
-
More Information
Article History
Received: 28 February 2018
Accepted: 18 March 2019
First Online: 1 April 2019
Ethics approval and consent to participate
: The research conducted by the OncoTrack consortium has been approved by the medical ethics committees of Charité – Universitätsmedizin Berlin (Berlin, Germany) and Medizinische Universität Graz (Graz, Austria). All participating patients gave written informed consent before participating in the research programme.
: Not applicable.
: Anthony Rowe is a full time employee and shareholder of Johnson and Johnson. Emmanuel Van der Stuyft is a full time employee and shareholder of Johnson and Johnson. Denny Verbeeck is a full time employee of Johnson and Johnson. David Henderson is a part time employee and shareholder of Bayer AG. Bodo Lange is a full time employee and CEO of Alacris Theranostics GmbH. Hans Lehrach is chairman of the company board of Alacris Theranostics GmbH.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
